Novel Peptides Show Promise Against Atherosclerosis by Targeting CD36
Background
Atherosclerosis, a chronic inflammatory disease, is the leading cause of cardiovascular morbidity and mortality worldwide, characterized by plaque buildup in arteries. Current therapies often focus on lipid lowering, but there's a critical need for treatments that can actively regress existing plaques or enhance their stability. This study investigates novel azapeptide derivatives of GHRP-6 as selective CD36 ligands for their potential to prevent and reverse atherosclerosis.
Results
Treatment with Aza-GHRP-6-X significantly reduced atherosclerotic plaque area in the aorta compared to vehicle-treated controls. The 1 mg/kg dose group exhibited a remarkable 52% reduction in plaque size (p<0.0001). > The most significant finding was the 3.1-fold increase in stable plaque features, such as collagen content, and a 48% decrease in vulnerable plaque components like macrophage infiltration within lesions. Furthermore, treated mice showed a 30% reduction in lipid accumulation within plaques and a 25% decrease in circulating pro-inflammatory cytokines like IL-6 compared to untreated controls, indicating a systemic anti-inflammatory effect. These results demonstrate both preventative and regressive capabilities.
Why It Matters
This research highlights the significant atheroprotective and atheroregressive potential of novel azapeptide derivatives, offering a new therapeutic strategy beyond traditional lipid-lowering approaches. By selectively targeting CD36 (a scavenger receptor involved in lipid uptake and inflammation), these peptides could stabilize existing plaques and prevent new ones from forming. These findings could pave the way for developing a new class of drugs to combat cardiovascular disease, potentially moving towards human clinical trials in the future. Further preclinical optimization and safety studies are the next crucial steps.